TGA / PMDA / NMPA · Asia-Pacific
teplizumab — TGA / PMDA / NMPA regulatory status
teplizumab (TEIZEILD) regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: NMPA clinical trials.
Status snapshot
- Status
- NMPA clinical trials
- Brand
- TEIZEILD
- Mechanism
- T-cell surface glycoprotein CD3 epsilon chain other
- Target
- T-cell surface glycoprotein CD3 epsilon chain
- Structured fields
- 5
Pharmacology context used for competitive intelligence: T-cell surface glycoprotein CD3 epsilon chain other. Target: T-cell surface glycoprotein CD3 epsilon chain. This page is a status aggregation for professional reference — not prescribing advice.
Regional decision snapshot — NMPA: clinical trials.
Linked evidence on this spoke: 0 published clinical programs and 0 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| NMPA | China | clinical trials | — | Evidence |
Related hubs
FAQ
What is the TGA / PMDA / NMPA approval status of teplizumab?
teplizumab currently shows NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get teplizumab regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.